Your browser doesn't support javascript.
loading
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura, Motoo; Oze, Isao; Kodaira, Takeshi; Abe, Tetsuya; Komori, Azusa; Narita, Yukiya; Masuishi, Toshiki; Taniguchi, Hiroya; Kadowaki, Shigenori; Ura, Takashi; Andoh, Masashi; Tachibana, Hiroyuki; Uemura, Norihisa; Tajika, Masahiro; Niwa, Yasumasa; Muto, Manabu; Muro, Kei.
Afiliação
  • Nomura M; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan. excell@hkg.odn.ne.jp.
  • Oze I; Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan. excell@hkg.odn.ne.jp.
  • Kodaira T; Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Abe T; Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Komori A; Department of Gastrointestinal Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Narita Y; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Masuishi T; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Taniguchi H; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Kadowaki S; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Ura T; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Andoh M; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Tachibana H; Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Uemura N; Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Tajika M; Department of Gastrointestinal Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Niwa Y; Department of Endoscopy, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Muto M; Department of Endoscopy, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
  • Muro K; Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan.
Int J Clin Oncol ; 21(5): 890-898, 2016 Oct.
Article em En | MEDLINE | ID: mdl-26980212
ABSTRACT

PURPOSE:

Our intent was to compare survival following neoadjuvant chemotherapy followed by surgery versus chemoradiotherapy (CRT) among patients with potentially resectable esophageal squamous cell carcinoma.

METHODS:

Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed. The survival outcomes were analyzed using the Kaplan-Meier method and propensity score-adjusted Cox proportional hazards models. Relevant variables were included in the propensity score model.

RESULTS:

Overall, 206 patients planned to undergo surgery (S group) and 200 patients planned to undergo CRT (CRT group). In the unadjusted situation, progression-free survival and overall survival did not differ statistically between the groups. After matching, both survival outcomes were better in the S group compared to the CRT group. Subanalysis showed both survival outcomes were better in the S group for patients with only stage III disease. However, survival outcomes for stages I, II, and IV were not significantly different between treatment groups.

CONCLUSIONS:

Among patients with resectable disease, survival outcomes in the S group were favored over those of the CRT group. These results indicate that different therapeutic strategies should be used for stage III esophageal cancer than for other stages.
Assuntos
Palavras-chave
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Protocolos de Quimioterapia Combinada Antineoplásica / Esofagectomia / Quimiorradioterapia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Clin Oncol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Japão
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Protocolos de Quimioterapia Combinada Antineoplásica / Esofagectomia / Quimiorradioterapia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Clin Oncol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Japão